These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 32317288

  • 21. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
    Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R.
    Cancer; 2018 Mar 15; 124(6):1288-1296. PubMed ID: 29211306
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes.
    Markowitz P, Patel M, Groisberg R, Aisner J, Jabbour SK, De S, Ganesan S, Malhotra J.
    Cancer Treat Res Commun; 2020 Mar 15; 25():100232. PubMed ID: 33166854
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y, Hamasaki M, Matsumoto S, Yoshimura M, Sato A, Tsujimura T, Kamei T, Kawahara K, Iwasaki A, Nabeshima K.
    Cancer Cytopathol; 2021 Jul 15; 129(7):526-536. PubMed ID: 33493384
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
    Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ.
    Oncotarget; 2016 Feb 16; 7(7):8321-31. PubMed ID: 26824986
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma.
    Zhang Y, Chen Y, Yang C, Seger N, Hesla AC, Tsagkozis P, Larsson O, Lin Y, Haglund F.
    Mod Pathol; 2021 Nov 16; 34(11):2020-2027. PubMed ID: 34108637
    [Abstract] [Full Text] [Related]

  • 34. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D.
    Oncogene; 2014 Oct 16; 33(42):4978-84. PubMed ID: 24141777
    [Abstract] [Full Text] [Related]

  • 35. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
    Torricelli F, Saxena A, Nuamah R, Neat M, Harling L, Ng W, Spicer J, Ciarrocchi A, Bille A.
    Eur J Cancer; 2020 Jun 16; 132():104-111. PubMed ID: 32339978
    [Abstract] [Full Text] [Related]

  • 36. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T, Brown TC, Juhlin CC, Andreasson A, Wang N, Bäckdahl M, Healy JM, Prasad ML, Korah R, Carling T, Xu D, Larsson C.
    Endocr Relat Cancer; 2014 Jun 16; 21(3):427-34. PubMed ID: 24803525
    [Abstract] [Full Text] [Related]

  • 37. Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
    Campanella NC, Silva EC, Dix G, de Lima Vazquez F, Escremim de Paula F, Berardinelli GN, Balancin M, Chammas R, Mendoza Lopez RV, Silveira HCS, Capelozzi VL, Reis RM.
    Pathobiology; 2020 Jun 16; 87(3):208-216. PubMed ID: 32369821
    [Abstract] [Full Text] [Related]

  • 38. TERT promoter mutation in adult granulosa cell tumor of the ovary.
    Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.
    Mod Pathol; 2018 Jul 16; 31(7):1107-1115. PubMed ID: 29449679
    [Abstract] [Full Text] [Related]

  • 39. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
    Blondy T, d'Almeida SM, Briolay T, Tabiasco J, Meiller C, Chéné AL, Cellerin L, Deshayes S, Delneste Y, Fonteneau JF, Boisgerault N, Bennouna J, Grégoire M, Jean D, Blanquart C.
    J Immunother Cancer; 2020 Jun 16; 8(1):. PubMed ID: 32581053
    [Abstract] [Full Text] [Related]

  • 40. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K.
    Acta Neuropathol; 2013 Aug 16; 126(2):267-76. PubMed ID: 23764841
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.